Metsera, Inc. (NASDAQ:MTSR – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $24.11 and last traded at $24.57, with a volume of 131556 shares changing hands. The stock had previously closed at $25.03.
Analyst Ratings Changes
A number of brokerages recently commented on MTSR. Evercore ISI initiated coverage on Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating on the stock. Guggenheim started coverage on Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target for the company. Cantor Fitzgerald began coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Finally, Bank of America assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective on the stock.
View Our Latest Analysis on MTSR
Metsera Trading Down 0.3 %
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- What is a penny stock? A comprehensive guide
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Expert Stock Trading Psychology Tips
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
